Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Unknown 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 23Lymphoma, Non-Hodgkin 18Leukemia, Myeloid, Acute 18Lymphoma, Large B-Cell, Diffuse 17Lymphoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lung Neoplasms 15Leukemia 13Carcinoma, Non-Small-Cell Lung 13Burkitt Lymphoma 13Recurrence 9Multiple Myeloma 9Lymphoma, Follicular 8Hodgkin Disease 8Leukemia, Lymphocytic, Chronic, B-Cell 7Congenital Abnormalities 7Lymphoma, B-Cell 6Sarcoma 5Neoplasms 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Sezary Syndrome 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Neuroblastoma 4Neoplasms, Plasma Cell 4Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4

Interventions

tislelizumab 1Paclitaxel 1Injections 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Extensive Stage Small Cell Lung Cancer × Etoposide × Clear all
NCT06897579 2026-04-28

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
40 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡